Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication.
Foskolou, Iosifina P
Leszczynska, Katarzyna B
Olcina, Monica M
Myers, William K
Hammond, Ester M
MetadataShow full item record
Foskolou, I. P., Jorgensen, C., Leszczynska, K. B., Olcina, M. M., Tarhonskaya, H., Haisma, B., D'Angiolella, V., et al. (2017). Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication.. Mol Cell, 66 (2), 206-220.e9. https://doi.org/10.1016/j.molcel.2017.03.005
Cells exposed to hypoxia experience replication stress but do not accumulate DNA damage, suggesting sustained DNA replication. Ribonucleotide reductase (RNR) is the only enzyme capable of de novo synthesis of deoxyribonucleotide triphosphates (dNTPs). However, oxygen is an essential cofactor for mammalian RNR (RRM1/RRM2 and RRM1/RRM2B), leading us to question the source of dNTPs in hypoxia. Here, we show that the RRM1/RRM2B enzyme is capable of retaining activity in hypoxia and therefore is favored over RRM1/RRM2 in order to preserve ongoing replication and avoid the accumulation of DNA damage. We found two distinct mechanisms by which RRM2B maintains hypoxic activity and identified responsible residues in RRM2B. The importance of RRM2B in the response to tumor hypoxia is further illustrated by correlation of its expression with a hypoxic signature in patient samples and its roles in tumor growth and radioresistance. Our data provide mechanistic insight into RNR biology, highlighting RRM2B as a hypoxic-specific, anti-cancer therapeutic target.
DNA damage response, P53, RNR, RRM2B, hypoxia, nucleotides, radiosensitivity, replication stress, Animals, Apoptosis, Cell Cycle Proteins, Colonic Neoplasms, DNA Damage, DNA Replication, DNA, Neoplasm, Female, HCT116 Cells, Humans, Mice, Inbred BALB C, Mice, Nude, Oxygen, RNA Interference, Radiation Tolerance, Ribonucleoside Diphosphate Reductase, Ribonucleotide Reductases, Time Factors, Transfection, Tumor Burden, Tumor Hypoxia, Tumor Suppressor Proteins, Xenograft Model Antitumor Assays
External DOI: https://doi.org/10.1016/j.molcel.2017.03.005
This record's URL: https://www.repository.cam.ac.uk/handle/1810/305258
Attribution-NonCommercial-NoDerivatives 4.0 International
Licence URL: https://creativecommons.org/licenses/by-nc-nd/4.0/
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: email@example.com